Pemetrexed
- Generic Name
- Pemetrexed
- Brand Names
- Alimta, Ciambra, Pemfexy, Pemrydi Rtu, Pemetrexed Fresenius Kabi, Pemetrexed Baxter, Pemetrexed Krka, Pemetrexed medac, Pemetrexed Accord, Pemetrexed Sandoz, Armisarte (previously Pemetrexed Actavis)
- Drug Type
- Small Molecule
- Chemical Formula
- C20H21N5O6
- CAS Number
- 137281-23-3
- Unique Ingredient Identifier
- 04Q9AIZ7NO
- Background
Pemetrexed is a chemotherapy drug that is manufactured and marketed by Eli Lilly and Company under the brand name Alimta. It is indicated for use in combination with cisplatin for the treatment of patients with malignant pleural mesothelioma whose disease is either unresectable or who are otherwise not candidates for curative surgery. Its use in non-small ce...
- Indication
Pemetrexed is indicated for the treatment of the following conditions:
Non-squamous non-small cell lung cancer (NSCLC)
Malignant pleural mesothelioma
- Associated Conditions
- Metastatic Cervical Cancer, Metastatic Non-squamous Non Small Cell Lung Cancer, Metastatic Urothelial Carcinoma (UC), Ovarian Cancer, Locally advanced nonsquamous non-small cell lung cancer, Recurrent, metastatic Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC), Unresectable Malignant Pleural Mesothelioma (MPM), Unresectable Thymoma
- Associated Therapies
- Monotherapy
Safety and Tolerability of IC83/LY2603618 Administered After Pemetrexed 500 mg/m2 Every 21 Days in Patients With Cancer
- First Posted Date
- 2006-12-25
- Last Posted Date
- 2018-10-19
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 31
- Registration Number
- NCT00415636
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Scottsdale, Arizona, United States
Pemetrexed Plus Cisplatin as First-Line Treatment in Stage IV or Recurrence of Gastric Cancer
- First Posted Date
- 2006-12-22
- Last Posted Date
- 2010-08-17
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 53
- Registration Number
- NCT00415168
- Locations
- 🇷🇺
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Stavropol, Russian Federation
A Study for Patients With Head and Neck Cancer
- Conditions
- Interventions
- First Posted Date
- 2006-12-22
- Last Posted Date
- 2011-06-28
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 795
- Registration Number
- NCT00415194
- Locations
- 🇨🇳
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Taipei, Taiwan
Chemotherapy for Patients With Non-Small Cell Lung Cancer Who Are Non-Smokers
- Conditions
- Interventions
- First Posted Date
- 2006-12-08
- Last Posted Date
- 2010-09-09
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 70
- Registration Number
- NCT00409006
- Locations
- 🇨🇳
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tao-Yuan, Taiwan
Safety Study of MKC-1 Combined With Pemetrexed to Treat Advanced Cancer and Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2006-12-06
- Last Posted Date
- 2012-01-20
- Lead Sponsor
- CASI Pharmaceuticals, Inc.
- Target Recruit Count
- 27
- Registration Number
- NCT00408226
- Locations
- 🇺🇸
University of Iowa, Iowa City, Iowa, United States
🇺🇸Indiana University Cancer Center, Indianapolis, Indiana, United States
🇺🇸University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States
Chemotherapy, Radiotherapy and Bevacizumab in Patients With Unresectable Stage III Non-Small-Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2006-11-22
- Last Posted Date
- 2021-11-09
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 5
- Registration Number
- NCT00402883
- Locations
- 🇺🇸
Wellstar Cancer Research, Marietta, Georgia, United States
🇺🇸Oncology Hematology Care, Cincinnati, Ohio, United States
🇺🇸Tennessee Oncology, PLLC, Nashville, Tennessee, United States
Cisplatin, Pemetrexed, and Imatinib Mesylate in Malignant Mesothelioma
- Conditions
- Interventions
- First Posted Date
- 2006-11-22
- Last Posted Date
- 2015-11-18
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 19
- Registration Number
- NCT00402766
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Chemotherapy With Pemetrexed in Combination With Platinum for Advanced Non-Small Cell Lung Cancer (NSCLC)
- Conditions
- Interventions
- First Posted Date
- 2006-11-22
- Last Posted Date
- 2010-02-17
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 133
- Registration Number
- NCT00402051
- Locations
- 🇩🇪
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Muenchen, Germany
Pemetrexed and Gemcitabine in Patients With Advanced Head and Neck Cancer
- First Posted Date
- 2006-10-31
- Last Posted Date
- 2022-08-05
- Lead Sponsor
- Fox Chase Cancer Center
- Target Recruit Count
- 17
- Registration Number
- NCT00394147
- Locations
- 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
Chemotherapy for Patients With Non-Small Cell Lung Cancer (NSCLC)
- First Posted Date
- 2006-10-23
- Last Posted Date
- 2011-04-12
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 211
- Registration Number
- NCT00391274
- Locations
- 🇨🇳
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Wu Han, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.